QART Medical News
13 articles
Ricerca israeliana: un metodo innovativo raddoppia il tasso di successo della fecondazione in vitro - Shalom
Innovadora tecnología israelí duplica las tasas de éxito de la fecundación in vitro
New Israeli tech doubles IVF success rates - ISRAEL21c
Breakthrough Israeli Technology Doubles IVF Success Rates, Offering Hope for Couples Struggling With Infertility - The Media Line
Breakthrough Israeli technology doubles IVF success rates
Innovative Israeli technology doubles IVF success rates
Tel Aviv Univ. Tech Doubles IVF Success
Israeli imaging startup addressing male factor infertility - Luminate
QART Medical, an Israeli-based imaging startup, is revolutionizing the IVF process by providing embryologists with advanced tools for selecting sperm cells. Their flagship product, the Q300™, offers real-time 3D analysis of sperm cells, enabling evidence-based decisions and improving IVF success rates. The company is currently conducting clinical trials at the UCSF Center for Reproductive Health and is in discussions with the University of Rochester Medical Center for further trials. QART Medical is also part of the Luminate NY accelerator program, which is helping them access capital and develop new partnerships. The company estimates a global market opportunity exceeding $1.3 billion, focusing initially on the U.S. and Japan.
PartnersExpand
QArt Medical: Helping the selection process in IVF treatment | CTech
QArt Medical, a clinical-stage medtech company specializing in quantitative assisted reproductive technologies, participated in Calcalists Israel-Japan 2023 conference. The company showcased its innovative QART system, which aims to improve IVF success rates through advanced 3D imaging and sperm selection technology. QArt Medical has raised $10 million to date and employs between 11-50 people. The conference provided an opportunity for QArt Medical to present its technology to senior executives from Japanese and international tech industries, potentially opening doors for new partnerships and investments.
InvestmentPartners
Swave Photonics, QART Medical, and PhosPrint win big at 2023 SPIE Startup Challenge
Improving IVF Treatments by Imaging Sperm Cells
Professor Natan Shaked has developed a new sperm cell imaging technique that could improve the outcomes of in vitro fertilisation (IVF) treatments. The technique uses holographic setups to visualise individual biological cells without staining, providing more information than regular staining. The technology has been developed into a clinical workstation by QART Medical, a company co-founded by Shaked. The company has built several clinical sperm imaging machines and is expected to start clinical trials soon. The research was funded by a HORIZON2020 ERC personal grant.
InvestmentExpand
Hamamatsu joins Seed Financing of QART Medical
Hamamatsu Photonics K.K. has joined Chartered Investment Managers, Tel Aviv University Technology Innovation Momentum Fund, Ramot, and a group of angel investors in a seed financing round for QART Medical. The round closed in March 2019. QART Medical, founded by Prof Natan T. Shaked and Alon Shalev, is a MedTech company that develops solutions for the global infertility epidemic. Hamamatsu Photonics K.K. is an industry leader in manufacturing photonics components and assemblies.
InvestmentPartners
QART Medical, founded by Prof Natan Shaked finalizes round of venture investment
QART Medical, a clinical-stage MedTech company, is developing a breakthrough solution for sperm cell selection in in-vitro fertilization (IVF) to improve success rates. The company is led by Prof. Natan T. Shaked, an associate professor in the Department of Biomedical Engineering at Tel Aviv University. The article highlights Prof. Shakeds research interests in biomedical optical microscopy, nanoscopy, and interferometry, with a focus on optical imaging and therapy for biomedical applications. The article does not mention any specific partners, customers, investment or acquisition amounts, layoffs, or a date of the event.
CustomersPartners
